In early-phase clinical trials, we observed a general decrease in tumor ADC following administration of PEGylated Recombinant Human Hyaluronidase PH20 (PEGPH20) as monotherapy. This decrease was related with reduction of tumor hyaluronan measured in biopsy samples. Reduction in ADC is suggestive of a decrease in tumor water content following hyaluronan depletion by PEGPH20.
This abstract and the presentation materials are available to members only; a login is required.